Table 1.
The characteristics of the populations.
| Clinical information of the 5 trials for the regimens | |||||||
| Reference | Tumor characteristics | Number of patient(control) | Median OS of patient(control) | Median PFS of patient(control) | Regimens | Course | |
| J. S. Chen 201518 |
ICC/ECC+GBC | 62(60) | 10.6(9.8) months | 6.7(4.1) months | Chemo+ cetuximab | 500mg/m2 cetuximab | 1 time/2 weeks until disease progression |
| David Malka 201417 |
BTC | 76(74) | 11(12.4) months | 6.1(4.0) months | Chemo+ cetuximab | 500 mg/m2 as a 150min intravenous infusion | 1 time/2 weeks until disease progression |
| Koichi Shimizu 201223 |
ICC | 36(26) | 31.9(17.4) months | 18.3(7.7) months | Surgery+ DC-CAT cells |
Postoperative adjuvant immunotherapy | Three at 2 months |
| Jeeyun Lee 201221 |
BTC | 135(133) | 9.5(9.5) months | 5.8(4.2) months | Chemo+ Erlotinib | 100 mg daily | 1 time/2 weeks until disease |
| Seung Tae Kim 201520 |
BTC | 54(49) | 11.4(9.5)months | 8.3(5.4)months | Chemo+ Erlotinib | 100 mg daily | 1 time/2 weeks until disease |
| Clinical information of the 7 trials for the immune prognostic factors | |||||||
| Reference | Tumor characteristics | Source | Period | Treatment | Factors | ||
| Ban Seok Lee 201614 |
CCA | Seoul National University Hospital |
2004-2013 | systemic chemotherapy | Neutrophil-lymphocyte ratio | ||
| Mariko Tsukagoshi 201611 |
ECC | Gunma University Hospital (Maebashi, Japan) or Saiseikai Maebashi Hospital (Maebashi, Japan) | 1995-2010 | surgery | NKG2D | ||
| Benjamin Goeppert 20159 |
BTC | The University Hospital Heidelberg | 1995-2010 | surgery | MHC I | ||
| Yu Jin Lim 201513 |
EHBD | Seoul National University College of Medicine and Medical Research Center, Seoul National University | 2000-2006 | surgery+CRT | PD-1+/CD8+ TILs | ||
| Benjamin Goeppert 20138 |
BTC | The University Hospital Heidelberg | 1995-2010 | surgery | Foxp3 intraepithelial | ||
| CD4 intraepithelial | |||||||
| Gu Fang-Ming 201210 |
ICC | Zhongshan Hospital | 2000-2006 | surgery | IL17+ | ||
| CD66b+ | |||||||
| TARO OSHIKIRI 200312 |
EHBD | Hokkaido University Hospital or Teine Keijinkai Hospital or Hokkaido Gastroenterology Hospital | 1992-1999 | surgery | CD8+ | ||
CCA: Cholangiocarcinoma; ECC: Extrahepatic cholangiocarcinoma; BTC: Biliary tract cancer; EHBD: Extrahepatic bile duct; ICC: Intrahepatic cholangiocarcinoma; GBC: Gallbladder cancer.